{
    "clinical_study": {
        "@rank": "95855", 
        "arm_group": [
            {
                "arm_group_label": "THS 2.2 Menthol", 
                "arm_group_type": "Experimental", 
                "description": "Ad libitum use of THS 2.2 Menthol"
            }, 
            {
                "arm_group_label": "SA", 
                "arm_group_type": "Sham Comparator", 
                "description": "Abstinence from smoking"
            }, 
            {
                "arm_group_label": "mCC", 
                "arm_group_type": "Active Comparator", 
                "description": "Ad libitum use of mCC"
            }
        ], 
        "brief_summary": {
            "textblock": "The main goal of the study is to evaluate if the ad libitum use of the THS 2.2 Menthol for 5\n      days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy\n      smokers results in a reduction in the levels of biomarkers of exposure for selected harmful\n      and potentially harmful constituents (HPHCs) compared to smokers continuing smoking their\n      own preferred brand of menthol conventional cigarette (mCC) and smoking abstinence (SA)."
        }, 
        "brief_title": "Reduced Exposure Study Using the Tobacco Heating System 2.2 (THS 2.2) Menthol for 91 Days in Confinement and Ambulatory", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Smoking, apparently healthy subject as judged by the Investigator.\n\n          -  Subject smokes at least 10 commercially available mCCs per day (no brand\n             restrictions) for the last 4 weeks, based on self-reporting.\n\n          -  Subject has smoked for at least the last 3 consecutive years.\n\n          -  Subject does not plan to quit smoking within the next 6 months.\n\n        Exclusion Criteria:\n\n          -  As per Investigator judgment, the subject cannot participate in the study for any\n             reason (e.g., medical, psychiatric, and/or social reason).\n\n          -  The subject has received medication within 14 days or within 5 half-lives of the\n             medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.\n\n          -  For women: Subject is pregnant or is breast feeding.\n\n          -  For women: Subject does not agree to use an acceptable method of effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989156", 
            "org_study_id": "ZRHM-REXA-08-US", 
            "secondary_id": "ZRHM-REXA-08-US"
        }, 
        "intervention": [
            {
                "arm_group_label": "THS 2.2 Menthol", 
                "description": "THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting", 
                "intervention_name": "THS 2.2 Menthol", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "SA", 
                "description": "SA for 5 days in confinement prolonged by 86 days in an ambulatory setting", 
                "intervention_name": "SA", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "mCC", 
                "description": "Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting", 
                "intervention_name": "mCC", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Menthol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking", 
            "Candidate modified risk tobacco product", 
            "Menthol conventional cigarettes", 
            "Reduced exposure", 
            "HPHCs", 
            "Ambulatory"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Frank Farmer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Daytona Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32117"
                    }, 
                    "name": "Covance Daytona Beach, 1900 Mason Ave., Suite 140"
                }, 
                "investigator": {
                    "last_name": "Frank Farmer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Lewis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75247"
                    }, 
                    "name": "Covance Dallas, 1341 W. Mockingbird Ln., Ste 400E"
                }, 
                "investigator": {
                    "last_name": "William Lewis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 91 Days", 
        "overall_contact": {
            "email": "William.Lewis@Covance.com", 
            "last_name": "William Lewis, MD", 
            "phone": "+1-214-920-9053"
        }, 
        "overall_contact_backup": {
            "email": "Farmer@Covance.com", 
            "last_name": "Frank Farmer, MD", 
            "phone": "+1-386-366-6400"
        }, 
        "overall_official": [
            {
                "affiliation": "Covance Dallas", 
                "last_name": "William Lewis, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Covance Daytona Beach", 
                "last_name": "Frank Farmer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Philip Morris Products S.A.", 
                "last_name": "Christelle Haziza, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To demonstrate the reduction of exposure to respectively 1,3-butadiene; acrolein; benzene HPHCs) after 5 days and to 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) after 91 days of switching from  mCC to THS 2.2 Menthol as compared to mCC.", 
                "measure": "The evaluation of the total levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA); total4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in 24 hours urine.", 
                "safety_issue": "No", 
                "time_frame": "MHBMA, 3-HPMA, S-PMA at 5 days; total NNAL at 91 days"
            }, 
            {
                "description": "To demonstrate the reduction of exposure to  carbon monoxide (CO) after 5 days of switching from  mCC to THS 2.2 Menthol as compared to mCC.", 
                "measure": "The evaluation of the total levels of carboxyhemoglobin (COHb) in blood.", 
                "safety_issue": "No", 
                "time_frame": "91 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}